Black Rock Inc. Point Biopharma Global Inc. Transaction History

Black Rock Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$6.67 - $9.71 $1.91 Million - $2.78 Million	285,792 Added 4.5%	6,635,892 $44.3 Million
Q2 2023 Aug 11, 2023	BUY	$6.86 - $10.86 $5.95 Million - $9.41 Million	866,833 Added 15.81%	6,350,100 $57.5 Million
Q1 2023 May 12, 2023	BUY	$6.78 - $8.1 $609,040 - $727,614	89,829 Added 1.67%	5,483,267 $39.9 Million
Q4 2022 Feb 13, 2023	SELL	$5.72 - $9.78 $4.34 Million - $7.42 Million	-759,159 Reduced 12.34%	5,393,438 $39.3 Million
Q3 2022 Nov 14, 2022	BUY	$7.24 - $10.31 $116,556 - $165,980	16,099 Added 0.26%	6,152,597 $47.6 Million
Q2 2022 Aug 12, 2022	BUY	$5.6 - $9.5 $19.6 Million - $33.2 Million	3,495,532 Added 132.36%	6,136,498 $41.8 Million
Q1 2022 May 12, 2022	SELL	$5.46 - $8.13 $1,894 - $2,821	-347 Reduced 0.01%	2,640,966 $21 Million
Q4 2021 Feb 10, 2022	BUY	$4.83 - $9.75 $4.4 Million - $8.87 Million	910,207 Added 52.58%	2,641,313 $14.8 Million
Q3 2021 Nov 09, 2021	BUY	$7.42 - $11.26 $12.8 Million - $19.5 Million	1,731,106 New	1,731,106 $13.3 Million

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.